Suppression of Radiation-Induced c-Met Activation Leads to Radiosensitization of Prostate Cancer Cells

Gao, Dehai; Bhuiyan, Manzerul; Yu, Lan; Takeshima, Tsuguhide; Hannan, Raquibul; Hsieh, Jer‐Tsong; Saha, Debabrata; Kim, D.

doi:10.1016/j.ijrobp.2014.05.683

International Journal of Radiation Oncology*Biology*Physics

2014

DOI: 10.1016/j.ijrobp.2014.05.683

|View full text |Cite

Suppression of Radiation-Induced c-Met Activation Leads to Radiosensitization of Prostate Cancer Cells

Dehai Gao

Manzerul Bhuiyan

Lan Yu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

MET Inhibition in Non-Small Cell Lung Cancer

Rehman

2019

EMJ

View full text Add to dashboard Cite

Cancer treatment paradigms have evolved over recent years with an emphasis on personalised medicine. Targeted agents are being used to improve treatment outcomes and quality of life. For the treatment of non-small cell lung cancer, several agents with unique genetic and epigenetic targets are available. To this extent, mesenchymal–epithelial transition (MET), a heterodimer receptor tyrosine kinase involved in embryogenesis and organogenesis, has been investigated as a potential target for biological agents. MET dysregulation can occur via different mechanisms and trigger tumourigenesis and disease spread. Besides driving the oncogenic dependence of cells, MET is also involved in acquired resistance to epidermal growth factor receptor inhibitors. As such, many small molecule kinase inhibitors and antibodies have been developed or are currently in different phases of clinical trials to counteract the MET-induced neoplastic activity. Some of these agents are selective while others are nonselective with multiple other potential targets. This article aims to present an overview of biological functioning of MET, its role in oncogenesis and resistance to treatment, and clinical studies evaluating MET inhibitors for treatment of non-small cell lung cancer.

show abstract

MET Inhibition in Non-Small Cell Lung Cancer

Rehman

2019

EMJ

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Suppression of Radiation-Induced c-Met Activation Leads to Radiosensitization of Prostate Cancer Cells

Cited by 1 publication

References 0 publications

MET Inhibition in Non-Small Cell Lung Cancer

MET Inhibition in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About